Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Diabetic Retinopathy Market: By Drug Type, By Route of Administration, By Distribution Channel, and Geography
Diabetic Retinopathy Market: By Drug Type, By Route of Administration, By Distribution Channel, and Geography
Diabetic Retinopathy Market size was valued at US$ 6.24 billion in 2023 and is poised to grow at a CAGR of 7.1% from 2024-2030. Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually affects people with diabetes for a number of years. High glucose levels in the cause damage to the retinal blood vessels is the main manifestation of diabetic retinopathy. In some other cases, the retinal blood vessels will be swollen (macular oedema) with a fluid leaking into rear of eye. In few cases, on the surface of the retinal blood vessels will grow abnormally. If diabetic retinopathy market is not properly treated, can progressively become more serious and seriously affect vision which may lead to blindness. Diabetic retinopathy can be treated by various methods depending on the stage of the disease. Diabetic retinopathy is one of the major causes of blindness in the adult population in America.
As per, the World Health Organisation (WHO), 347 Mn people were suffering from diabetes globally in 2012, in which 11% population had diabetic retinopathy. An increase in focus on Asia-Pacific and LAMEA regions by various vendors is expected to boost the diabetic retinopathy market growth of the market According to the World Bank, in 2015,10.4% of rate of prevalence of diabetes was observed in Brazil. Strategic acquisitions, geographic expansion, agreements, partnerships, and new product launches are the most vital strategic implementations by most of the companies in the market of diabetic retinopathy.
Study Period
2024-2030Base Year
2023CAGR
7.1%Largest Market
North AmericaFastest Growing Market
Europe
Diabetic Retinopathy will affect both type 1 and type 2 diabetic patients and due to the abundant increase in the pool of patients with Diabetes, According to the World Health Organisation (WHO), 41 % of global population with diabetes are geriatric patients which is highly attributing the growth of the diabetic retinopathy market. Furthermore, rise in healthcare infrastructure up-gradation, rise in demand for the early diagnosis devices are the few factors having significant impact in driving the diabetic retinopathy market. However, paucity of skilled ophthalmologist, lack of primary infrastructure and insurance facilities are some of the restraining factors that are hampering the growth of diabetic retinopathy market.
On the basis of regions, the global market of diabetic retinopathy has been segmented into five key regions, Latin America North America, Asia-Pacific, Europe, and Middle East & Africa. North America dominates the market followed by Asia-Pacific and Europe. The factors that are attributing for the market growth in North America are, people with high obesity rates are more prone to diabetes conditions. Large patient pool in European region with diabetic retinopathy is expected to drive the growth of the market. In emerging economies, due to the improvement in the healthcare infrastructure and rise in awareness in the people Owing to improved infrastructure and awareness among the people, improving on the quality of life (QALY) in diabetic patients, rise in demand of early detection and treatment of chronic conditions such as diabetic retinopathy are the factors that are driving the growth of the diabetic retinopathy market in Asia Pacific regions.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 6.24 billion |
|
Market CAGR |
7.1% |
|
By Type |
|
|
By Drug Class |
|
|
By Distribution Channel |
|
Download Free Sample Report
The diabetic retinopathy market size was valued at US$ 6.24 billion in 2023
Abbott Laboratories (U.S.), Alimera Sciences (U.S.), Allergan plc (Ireland.), Ampio Pharmaceuticals. (U.S.), Bayer AG (Germany), F. Hoffmann-La Roche (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Valeant (Canada)
Europe is the fastest-growing region in the diabetic retinopathy market
| 1. Executive Summary |
| 2. Global Diabetic Retinopathy Market Introduction |
| 2.1. Global Diabetic Retinopathy Market - Taxonomy |
| 2.2. Global Diabetic Retinopathy Market - Definitions |
| 2.2.1. Drug Type |
| 2.2.2. Route of Administration |
| 2.2.3. Distribution Channel |
| 3. Global Diabetic Retinopathy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Diabetic Retinopathy Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Global Diabetic Retinopathy Treatment Market Competition Landscape |
| 4. Global Diabetic Retinopathy Market, By Drug Type, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 4.1. Aflibercept |
| 4.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.3. Market Opportunity Analysis |
| 4.2. Ranibizumab |
| 4.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.3. Market Opportunity Analysis |
| 4.3. Corticosteroids |
| 4.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.3.3. Market Opportunity Analysis |
| 4.4. Others |
| 4.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 4.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.4.3. Market Opportunity Analysis |
| 5. Global Diabetic Retinopathy Treatment Market Forecast, By Route of Administration, 2019 - 2023 and Forecast, 2021 2027 (Revenue, USD Mn) |
| 5.1. Oral |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Parenteral |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Diabetic Retinopathy Treatment Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 6.1. HOSPITAL PHARMACIES |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. RETAIL PHARMACIES |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. ONLINE PHARMACIES |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Diabetic Retinopathy Treatment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel and Region, 2024-2030 |
| 8. North America Diabetic Retinopathy Treatment MarketAnalysis,2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 8.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Aflibercept |
| 8.1.2. Ranibizumab |
| 8.1.3. Corticosteroids |
| 8.1.4. Others |
| 8.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 8.2.1. Oral |
| 8.2.2. Parenteral |
| 8.2.3. Others |
| 8.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. HOSPITAL PHARMACIES |
| 8.3.2. RETAIL PHARMACIES |
| 8.3.3. ONLINE PHARMACIES |
| 8.4. Country Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.4.1. USA |
| 8.4.2. Canada |
| 8.5. North America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 8.6. North America Diabetic Retinopathy Treatment Market Dynamics Trends |
| 9. Europe Diabetic Retinopathy Treatment Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 9.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Aflibercept |
| 9.1.2. Ranibizumab |
| 9.1.3. Corticosteroids |
| 9.1.4. Others |
| 9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Oral |
| 9.2.2. Parenteral |
| 9.2.3. Others |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. HOSPITAL PHARMACIES |
| 9.3.2. RETAIL PHARMACIES |
| 9.3.3. ONLINE PHARMACIES |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. Germany |
| 9.4.2. UK |
| 9.4.3. France |
| 9.4.4. Spain |
| 9.4.5. Italy |
| 9.4.6. Russia |
| 9.4.7. Poland |
| 9.4.8. Rest of Europe |
| 9.5. Europe Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 9.6. Europe Diabetic Retinopathy Treatment Market Dynamics Trends |
| 10. Asia-Pacific Diabetic Retinopathy Treatment Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 10.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Aflibercept |
| 10.1.2. Ranibizumab |
| 10.1.3. Corticosteroids |
| 10.1.4. Others |
| 10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Oral |
| 10.2.2. Parenteral |
| 10.2.3. Others |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. HOSPITAL PHARMACIES |
| 10.3.2. RETAIL PHARMACIES |
| 10.3.3. ONLINE PHARMACIES |
| 10.4. Country Analysis2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Japan |
| 10.4.2. China |
| 10.4.3. India |
| 10.4.4. ASEAN |
| 10.4.5. Australia & New Zealand |
| 10.4.6. Rest of Asia-Pacific |
| 10.5. Asia-Pacific Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 10.6. Asia-Pacific Diabetic Retinopathy Treatment Market Dynamics Trends |
| 11. Latin America Diabetic Retinopathy Treatment Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 11.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Aflibercept |
| 11.1.2. Ranibizumab |
| 11.1.3. Corticosteroids |
| 11.1.4. Others |
| 11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Oral |
| 11.2.2. Parenteral |
| 11.2.3. Others |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. HOSPITAL PHARMACIES |
| 11.3.2. RETAIL PHARMACIES |
| 11.3.3. ONLINE PHARMACIES |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Brazil |
| 11.4.2. Mexico |
| 11.4.3. Argentina |
| 11.4.4. Rest of Latin America |
| 11.5. Latin America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 11.6. Latin America Diabetic Retinopathy Treatment Market Dynamics Trends |
| 12. Middle East and Africa Diabetic Retinopathy Treatment Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn) |
| 12.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Aflibercept |
| 12.1.2. Ranibizumab |
| 12.1.3. Corticosteroids |
| 12.1.4. Others |
| 12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Oral |
| 12.2.2. Parenteral |
| 12.2.3. Others |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. HOSPITAL PHARMACIES |
| 12.3.2. RETAIL PHARMACIES |
| 12.3.3. ONLINE PHARMACIES |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Gulf Cooperation Council (GCC) Countries |
| 12.4.2. Israel |
| 12.4.3. South Africa |
| 12.4.4. Rest of MEA |
| 12.5. MEA Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030 |
| 12.6. MEA Diabetic Retinopathy Treatment Market Dynamics Trends |
| 13. Global Diabetic Retinopathy Treatment - Pipeline Drug Analysis |
| 13.1. Global Diabetic Retinopathy Treatment Disease Epidemiology |
| 13.2 Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment |
| 13.3. Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment - Sponsors/Companies |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Regeneron Pharmaceuticals |
| 14.2.2. Novartis AG |
| 14.2.3. Genentech |
| 14.2.4. Novartis AG |
| 14.2.5. Bayer AG |
| 14.2.6. Oxurion |
| 14.2.7. OccuRx |
| 14.2.8. AptaBio Therapeutics |
| 14.2.9. Kodiak Sciences |
| 14.2.10. RemeGen |
| 14.2.11. F. Hoffman-La-Roche AG. |
| 14.2.12. Grifols S.A. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronymsc |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.